280 related articles for article (PubMed ID: 8552200)
1. Human hematopoietic cell lines: a model system for study of minimal residual disease detection technique in acute leukemia.
Koníková E; Kusenda J; Babusíková O; Glasová M
Neoplasma; 1995; 42(5):227-34. PubMed ID: 8552200
[TBL] [Abstract][Full Text] [Related]
2. Detection of cytoplasmic and surface membrane markers in cells of some human hematopoietic cell lines.
Koníková E; Babusíková O; Kusenda J; Glasová M
Neoplasma; 1992; 39(6):337-42. PubMed ID: 1491722
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of different fixation-permeabilization methods for simultaneous detection of surface, cytoplasmic markers and DNA analysis by flow cytometry in some human hematopoietic cell lines.
Glasová M; Koníková E; Kusenda J; Babusíková O
Neoplasma; 1995; 42(6):337-46. PubMed ID: 8592577
[TBL] [Abstract][Full Text] [Related]
4. Leukemia-associated marker combinations in acute leukemia suitable for detection of minimal residual disease.
Babusíková O; Mesárosová A; Koníková M; Kusenda J; Glasová M; Klobusická M
Neoplasma; 1993; 40(5):275-81. PubMed ID: 8272155
[TBL] [Abstract][Full Text] [Related]
5. The reliability of cytoplasmic CD3 and CD22 antigen expression in the immunodiagnosis of acute leukemia: a study of 500 cases.
Janossy G; Coustan-Smith E; Campana D
Leukemia; 1989 Mar; 3(3):170-81. PubMed ID: 2465463
[TBL] [Abstract][Full Text] [Related]
6. Some early differentiation markers detected in cytoplasm of pre-B cells by flow cytometry.
Koníková E; Glasová M; Kusenda J; Babusíková O
Neoplasma; 1996; 43(6):373-9. PubMed ID: 8996561
[TBL] [Abstract][Full Text] [Related]
7. Detection of intracellular lymphoid differentiation antigens by flow cytometry in acute lymphoblastic leukemia.
Sartor M; Bradstock K
Cytometry; 1994 Sep; 18(3):119-22. PubMed ID: 7813331
[TBL] [Abstract][Full Text] [Related]
8. Flow cytometric analysis of cell-surface and intracellular antigens in leukemia diagnosis.
Knapp W; Strobl H; Majdic O
Cytometry; 1994 Dec; 18(4):187-98. PubMed ID: 7534675
[TBL] [Abstract][Full Text] [Related]
9. Different expression of CD3 and CD22 in leukemic cells according to whether tested in suspension or fixed on slides.
Rani S; De Oliveira MS; Catovsky D
Hematol Pathol; 1988; 2(2):73-8. PubMed ID: 2974027
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy.
Ghetie MA; May RD; Till M; Uhr JW; Ghetie V; Knowles PP; Relf M; Brown A; Wallace PM; Janossy G
Cancer Res; 1988 May; 48(9):2610-7. PubMed ID: 2451562
[TBL] [Abstract][Full Text] [Related]
11. B cell antigen receptor-mediated apoptosis. Importance of accessory molecules CD19 and CD22, and of surface IgM cross-linking.
Chaouchi N; Vazquez A; Galanaud P; Leprince C
J Immunol; 1995 Apr; 154(7):3096-104. PubMed ID: 7534787
[TBL] [Abstract][Full Text] [Related]
12. Flow cytometric detection of some activation and proliferation markers in human hematopoietic cell lines.
Glasová M; Koníková E; Kusenda J; Babusíková O
Neoplasma; 1996; 43(6):381-8. PubMed ID: 8996562
[TBL] [Abstract][Full Text] [Related]
13. [Analysis of cytoplasmic antigens in acute leukemia by flow cytometry].
Kawai S; Zha Z; Yamamoto Y; Nakadate H; Kawakami K; Kikuta A; Utsumi J; Nishikawa K; Mimaya J; Miyake M
Rinsho Ketsueki; 1993 Jan; 34(1):13-20. PubMed ID: 8450602
[TBL] [Abstract][Full Text] [Related]
14. Flow cytometry of peripheral blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells, lymphocyte subsets and detection of minimal residual disease after treatment.
Babuŝíková O; Tomová A; Kusenda J; Gyárfás J
Neoplasma; 2001; 48(5):350-7. PubMed ID: 11845978
[TBL] [Abstract][Full Text] [Related]
15. Concomitant delineation of surface Ig, B-cell differentiation antigens, and HLADR on lymphoid proliferations using three-color immunocytometry.
Segal GH; Edinger MG; Owen M; McNealis M; Lopez P; Perkins A; Linden MD; Fishleder AJ; Stoler MH; Tubbs RR
Cytometry; 1991; 12(4):350-9. PubMed ID: 1712263
[TBL] [Abstract][Full Text] [Related]
16. Flow cytometric determination of leukemia-associated marker combinations for the study of minimal residual disease.
Babusíková O; Glasová M; Kusenda J; Koníková E; Mésárosová A
Neoplasma; 1994; 41(6):305-13. PubMed ID: 7870213
[TBL] [Abstract][Full Text] [Related]
17. Leukemia-associated phenotypes: their characteristics and incidence in acute leukemia.
Babusíková O; Glasová M; Koníková E; Kusenda J
Neoplasma; 1996; 43(6):367-72. PubMed ID: 8996560
[TBL] [Abstract][Full Text] [Related]
18. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties.
Carnahan J; Wang P; Kendall R; Chen C; Hu S; Boone T; Juan T; Talvenheimo J; Montestruque S; Sun J; Elliott G; Thomas J; Ferbas J; Kern B; Briddell R; Leonard JP; Cesano A
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3982S-90S. PubMed ID: 14506197
[TBL] [Abstract][Full Text] [Related]
19. A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma.
Vallera DA; Todhunter DA; Kuroki DW; Shu Y; Sicheneder A; Chen H
Clin Cancer Res; 2005 May; 11(10):3879-88. PubMed ID: 15897589
[TBL] [Abstract][Full Text] [Related]
20. Delivery of saporin to human B-cell lymphoma using bispecific antibody: targeting via CD22 but not CD19, CD37, or immunoglobulin results in efficient killing.
Bonardi MA; French RR; Amlot P; Gromo G; Modena D; Glennie MJ
Cancer Res; 1993 Jul; 53(13):3015-21. PubMed ID: 7686448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
